Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer
1 other identifier
observational
45
1 country
1
Brief Summary
The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2013
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2016
CompletedFirst Submitted
Initial submission to the registry
March 14, 2017
CompletedFirst Posted
Study publicly available on registry
April 19, 2017
CompletedApril 19, 2017
April 1, 2017
2.5 years
March 14, 2017
April 18, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Change of maximal inspiratory pressure (MIP)
Change from baseline MIP at the end of each week's treatment, and 2 weeks after the completion of treatment
Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of diaphragmatic surface electromyography (EMGdi)
Change from baseline EMGdi at the end of each week's treatment, and 2 weeks after the completion of treatment
Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of forced expiratory volume in one second (FEV1)
Change from baseline FEV1 at the end of each week's treatment, and 2 weeks after the completion of treatment
Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of forced vital capacity (FVC)
Change from baseline FVC at the end of each week's treatment, and 2 weeks after the completion of treatment
Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Secondary Outcomes (2)
Change of functional exercise capacity
Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Change of dyspnea
Baseline, weekly during treatment, and 2 weeks after the completion of treatment
Eligibility Criteria
newly diagnosed primary esophageal cancer
You may qualify if:
- newly diagnosed primary esophageal cancer, aged more than 20 years, and communicate without difficulty
You may not qualify if:
- inability to perform inspiratory muscle training, the presence of unstable angina or myocardial infarction in recently one month, cannot cooperate with training protocols, and pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mackay Memorial Hospital
Taipei, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- VS. Division of Radiation Oncology, Department of Radiology
Study Record Dates
First Submitted
March 14, 2017
First Posted
April 19, 2017
Study Start
August 1, 2013
Primary Completion
February 1, 2016
Study Completion
February 1, 2016
Last Updated
April 19, 2017
Record last verified: 2017-04